Bioluminescence creates a stir

Article

In the world of preclinical research, bioluminescence imaging is creating a stir. Like fluorescence imaging, it enables the visualization of genetic expression and physiological processes at the molecular level in living tissues. But because there is no competing background signal, it can be used to detect much lower levels of light.

Another key difference between the two optical imaging methods is that bioluminescence does not rely on an external light source. Instead, borrowing from nature (usually a firefly), bioluminescence imaging detects light that is emitted from within experimental animals through the action of luciferase on its substrate, luciferin. Finally, because luciferase imaging requires genetic transfection, it is unlikely to ever find a place in human studies, although it can be useful for predicting human response to therapy in the early stages of drug development.

During imaging, an anesthetized mouse is placed in a dark chamber, and a photographic image is taken. Sensitive CCD cameras are used to capture the bioluminescent data, which are superimposed on the photographic image for easier interpretation.

Luciferase can be incorporated into a wide array of cells, organisms, and genes. Bioluminescence imaging has been used primarily to track tumor and immune system cells, bacterial and fungal infections, and gene expression.

Prostate tumor cells, for example, can be transfected with the luciferase gene. Once they are injected into mice, bioluminescence imaging can be used to monitor tumor growth and metastasis and to gauge the response to chemotherapy.

Xenogen in Alameda, CA, has even incorporated luciferase into a line of light-producing transgenic animals, including one that can detect tumor-associated angiogenesis. In this case, the gene for a vascular endothelial growth factor (VEGF) surface receptor promoter is incorporated into a mouse chromosome along with a gene for luciferase. When VEGF is secreted during angiogenesis, induction of the VEGF promoter prompts production of luciferase as well.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.